Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Zidovudine Plus Lamivudine in HTLV-I-Associated Myelopathy: a Randomised Trial
This study has been completed.
Study NCT00272480 Information provided by Imperial College London
First Received: January 4, 2006 Last Updated: June 27, 2007
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HTLV-I-Associated Myelopathy
Additional conditions recognized in this trial
HTLV-I Infections
Paraparesis, Tropical Spastic
Spinal Cord Diseases
More general conditions related to this trial
Central Nervous System Diseases
Central Nervous System Infections
Central Nervous System Viral Diseases
Deltaretrovirus Infections
Immune System Diseases
Immunologic Deficiency Syndromes
Myelitis
Nervous System Diseases
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
Zidovudine/lamivudine
Additional drug interventions recognized in this trial
Lamivudine
Zidovudine
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antimetabolites
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Imperial College London
Back to top of Main Content
